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Summary This paper describes a prospective immunohistochemical analysis of 27 kDa heat shock protein
(HSP27) in 361 patients with primary breast cancer in relation to disease-free survival (DFS) and survival
from first relapse (SR). Oestradiol (ER) and progesterone (PR) receptors were also quantitated and related to
the HSP27 data. While ER positively predicted a good outcome for both DFS and SR, HSP27 positivity
predicted a prolonged SR but short DFS. The association between HSP27 and DFS only attained statistical
significance in node-negative patients. Subgroup analysis reinforced the complementary relationship of HSP27
and ER for SR and opposing influences for DFS. In both node-negative and node-positive women, ER'
HSP27- patients had a longer DFS than ER- HSP27+ counterparts. There was no relationship between
HSP27 and overall survival. HSP27 staining was highly correlated with ER but not PR, patient age, tumour
size or menstrual status. There was a marginal correlation (P = 0.04) with histological grade with well-
differentiated tumours having the highest HSP27. Cox multivariate regression analysis of the contribution of
HSP27 in the presence of data on ER, PR, stage, nodal status and histological grade indicated that HSP27
was not of independent prognostic importance for DFS or overall survival and was only of borderline
significance for OS (P<0.07). However, in the absence of ER and PR data, HSP27 staining is an effective way
of getting the same prognostic infonnation. HSP27 staining appears to correlate with different biological
features in early and advanced breast, high HSP27 being linked with short DFS in node-negative patients but
with prolonged survival from first recurrence.
Much effort has been directed at analysing hormone and
growth factor receptors, oncogene products and indices of
cell proliferation in human breast cancers with results ofboth
biological and clinical importance (Sutherland & McGuire,
1991; Davidson & Abeloff, 1992). We have been interested in
a different type of protein, a low molecular weight (27 kDa)
heat shock protein (HSP27). This is an abundant protein that
has previously been discussed under three different names,
p29 (King, 1986; King et al., 1987), p24 (Ciocca et al., 1983;
Adams & McGuire, 1985) and srp27 (Thor et al., 1991), but
it is now known that they are one and the same protein
(Mendelsohn et al., 1991; Ciocca & Luque, 1991) and will
henceforth be called HSP27. HSP27 is a widely distributed
protein, although levels attained in breast cancers exceed
those found in other cells (Dunn et al., 1993). Its functions
are unknown although by analogy with the larger members
of the heat shock protein family it may be involved in
regulating the structure, intracellular transport or secretion of
other proteins (Georgopoulos, 1992; Gething & Sambrook,
1992). A number of reports link HSP27 expression with
certain types of drug resistance (Dunn et al., 1993), viral
neoplasia (Zantema et al., 1989) and a range of normal cell
functions (Dunn et al., 1993), but it is difficult to get a clear
picture of the biological roles of HSP27 from these fragment-
ary data. Interest in this protein has derived from several
separate lines of work. Its association to oestrogen action has
been most extensively studied as HSP27 is qualitatively and
quantitatively related to ER in a range of oestrogen-sensitive
cells including primary breast cancers (Dunn et al., 1993).
Like ER, HSP27 predicts for hormone sensitivity of
advanced breast cancers (King et al., 1987) and will react
with specific forms of ER (Coffer et al., 1985a; Coffer &
King, 1988). Furthermore, HSP27 is expressed in increased
amounts in invasive breast cancers as compared with car-
cinoma in situ, which in turn has more than normal mam-
mary epithelium (King et al., 1987; Girling et al., 1988).
It has also been reported that elevated levels of HSP27 are
prognostic for rapid recurrence of breast cancer (Tandon et
al., 1990; Thor et al., 1991), which is at variance with its
positive correlation with ER, high levels of which predict for
long disease-free survival (McGuire, 1987; Jordan et al.,
1988). No previous publication comments on this anomaly or
presents data on survival from first recurrence. From the
correlation with ER and with response to hormones, high
levels of HSP27 would be expected to indicate long such
survival.
To clarify the role of HSP27, we studied the effects of
HSP27 and ER on disease-free survival, survival from first
recurrence and overall survival on a prospective series of 361
primary breast cancers from women attending a single clinic.
Materials and methods
Patients
Tumours were obtained over a 3 year period from patients
with operable breast cancer treated either by modified radical
mastectomy or by excision of tumour followed by
radiotherapy. The only tumours omitted were those for
which histopathology and ER analysis utilised all the
material. Of the 452 tumours assembled, 91 were excluded
for having locally advanced or metastatic disease (86), car-
cinoma in situ (4) or loss to follow-up (1). This analysis is
therefore based on 361 patients with stage 1 or 2 disease.
Median follow-up from diagnosis (using the time when the
Kaplan-Meier plot, with event status reversed, passes
through 50%) was 6 years 2 months.
Tissues and staining
Tissues were fixed in methacarn (methanol-chloroform-acetic
acid; 60:30:10) and immediately processed as described
previously (Cano et al., 1986). The present data are primarily
derived from the samples described in that report. The
monoclonal antibody D5 against HSP27 has been described
elsewhere (Coffer et al., 1985; King & Coffer, 1986). It is
human specific and in immunoblots of tissue extracts recog-
nises only HSP27. In histochemistry it recognises HSP27 in
alcohol- and methacarn-fixed tissues, but is ineffective with
other fixatives. Sections were stained for 1 h with antibody
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D5 (8 ytg of protein per ml) and, after washing for 45 min,
with a 1:50 dilution of peroxidase-conjugated sheep anti-
mouse IgG (Amersham International, Amersham, UK) con-
taining 1:25 dilution of human serum. Peroxidase was
identified with diaminobenzidine plus hydrogen peroxide.
Quantitation ofstaining in breast tumour sections
Tumour cellularity, staining intensity and proportion of
positive tumour cells were assessed by eye as previously
described (Cano et al., 1986). The proportion of tumour cells
per section was assessed by eye and allocated a score of 0-6.
Staining intensity was estimated on a 0-3 + scale. The stain-
ing index was a simple multiple of the cellularity and staining
scores. This method of quantitation was selected to success-
fully facilitate comparison with biochemical assays, which are
a combination of antigen per cell and no. of antigen-
containing cells (Cano et al., 1986). As described in the
Results section, some statistical comparisons were made in
which either stain intensity or cellularity was assessed
independently. In no case did these methods of quantitation
alter the conclusions obtained by using stain index. Two
sections were stained, and values calculated as a mean of the
two individual values. Unless stated otherwise a staining
index of greater than 2.0 was taken as positive. This value
was selected on the basis of being the lowest value at which
separate observers agreed a sample was positive. The index
value of 7 used to separate high and moderate HSP27 stain-
ing was selected as the value above which the highest percen-
tage of tumours responded to hormone therapy (data not
shown).
Results
General characteristics
HSP27 staining correlated with ER but not PR, age, tumour
size, nodal status, stage or menstrual status (Table I). His-
tological grade 1 tumours had lower HSP27 staining than the
less well-differentiated grade 2 and 3 tumours. Twenty-seven
per cent of all tumours had low HSP27, while the propor-
tions of the four ER, HSP27 phenotypes were ER' HSP27+
66%, ER- HSP27- 9%, ER' HSP27- 18% and ER-
HSP27+ 7%.
Table I Correlation of HSP27 with other variables
Correlation
coefficient P-value
Continuous variable
ER 0.245 0.001
PR 0.105 >0.05
Age - 0.06 >0.05
Tumour size - 0.08 >0.05
Discrete variablea
Stage 5.87 0.05
Nodal status 1.43 0.2
Menstrual status 0.77 0.9
Histological grade 6.36 0.04
aKruskal-Wallis test.
Oestradiol andprogesterone receptor assays
Ligand-binding assays were performed as previously des-
cribed (King et al., 1977). A value of >20 fmol per mg of
protein was taken as positive.
Statistical methods
For disease-free survival (DFS), time was measured from
histological diagnosis to recurrence, death or date of last
follow-up. Patients who died from a known cause other than
breast cancer, with the patients thought to be in remission,
and those not known to have relapsed or died, had censored
survival times. For survival from first recurrence (SR), time
was measured from date of recurrence to death or date of
last follow-up. Events were death from breast cancer, death
with breast cancer present and uncertain cause of death.
Patients dying from a known cause, with their breast cancer
thought to be in remission, and those not known to have
died, had censored survival times.
For overall survival (OS), time was measured from date of
diagnosis to death or last follow-up. Events were death from
breast cancer, death with breast cancer present and uncertain
cause of death. Patients dying from a known cause with
breast cancer in remission and those not known to have died
had censored survival times.
Graphs of survival were drawn using the Kaplan-Meier
method and univariate survival analysis of categorical
variables was by the log-rank test (Peto et al., 1977). For
continuous variables, univariate Cox analysis was used to
avoid setting cut-off points (Cox, 1972). Variables significant
at P = <0.1 in the univariate analysis were put into a step-
wise Cox regression model to discover which were the
strongest independent predictors. In the Cox model, a
negative coefficient indicates a positive relationship of the
variable with survival and vice versa.
Progesterone receptors had a skew distribution, so to avoid
the few large values having an unduly large effect the natural
logarithm of progesterone receptor is used in the Cox regres-
sion analysis.
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Figure 1 Influence of oestradiol receptor a and HSP27 b levels
on disease-free survival. a, Values are fmol per mg of protein.
The numbers of patients at risk at 5 years are 0-9 = 25,
10-19 = 9, 20-999 = 119. Chi-square 8.005, P = 0.018. b, Values
are stain index as defined in Materials and methods. The
numbers of patients at risk at 5 years are 0-2 = 46, 2.1-7 = 73,
7.1-25=42. Chi-square 3.49, P=0.175.HSP27 IN BREAST CANCER 745
Disease-free survival (DFS)
There were 361 patients and 174 events. Considering all
patients, ER (Figure la) was significantly associated with
DFS (univariate Cox, coefficient = - 0.001, standard error
0.0004, P = 0.002) and HSP27 (Figure Ib) was approaching
significance (univariate Cox, coefficient = 0.03, standard
error = 0.017, P = 0.07). However, the coefficient for ER is
negative, indicating a positive effect with DFS, and the
coefficient for HSP27 is positive, indicating a negative effect
with survival. This was unexpected given the correlation
between ER and HSP27 and between high ER and long
DFS. HSP27 was only prognostic in node-negative patients
(Figure 2).
As high ER and HSP27 had opposing influences on DFS
in the node-negative group, their combined effects were
analysed in all patients and the separate nodal subgroups.
The ER' HSP27- phenotype exhibited the longest DFS,
whereas the ER- HSP27+ tumours recurred more rapidly.
This was true for all patients (Figure 3a) and after separation
into node-negative (Figure 3b) and -positive (Figure 3c) sub-
groups. In the node-negative group the worst prognosis was
exhibited by ER- HSP27+ patients, whereas ER- HSP27-
patients had the worst prognosis in the node-positive group.
Patients with ER' HSP27+ tumours did worse than those
with ER- HSP27- tumours in all three categories. In the
node-positive patients, ER phenotype exerted a stronger
influence on tumour behaviour than HSP27, as both the ER'
HSP27+ and ER' HSP27- categories had longer DFS than
the ER- HSP27+ and ER- HSP27- groups. However, using
the best method ofconsidering differing influences of ER and
HSP27 in nodal subgroups (i.e. by including an interaction
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term in a Cox model), it would not be concluded that the
effects in the nodal subgroups differed (i.e. the interaction
term was not significant).
Survivalfromfirst recurrence (SR)
There were 171 patients and 114 events. Both ER (Figure 4a)
and HSP27 (Figure 4b) were significantly correlated with SR
(univariate Cox, coefficient for ER = - 0.002, standard
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Figure 2 Influence of HSP27 levels on disease-free survival in
node-positive a or node-negative b patients. HSP levels are as
defined in Figure 1. The numbers ofpatients at risk at 5 years are
a, 0-2 = 9, 2.1-7 = 21, 7.1-25 = 16. Chi-square 0.203,
P = 0.903. b, 0-2 = 30, 2.1-7 = 40, 7.1-25 = 20. Chi-square
7.293, P = 0.026.
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Figure 3 Influence of combined oestradiol receptor (ER) and
HSP27 (I) phenotypes on disease-free survival in: a, all patients;
b, node-negative patients; c, node-positive patients.
ER + >20 fmol mg' protein; I = >2 index. The numbers of
patients at risk at 5 years are: a, ER' I+ = 105, ER' 1- = 31,
ER- I- = 15, Chi-square 8.119, P= 0.044; b, ER+ I+ = 53, ER-
I = 7, ER' I- = 18, ER- I- = 12, Chi-square 8.682, P = 0.034;
c, ER+ I = 35, ER- I+ = 2, ER+ I- = 8, ER- I- = 1, Chi-
square 16.68, P = <0.001.
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error = 0.0006, P = 0.003, coefficient for HSP27 = - 0.081,
standard error = 0.0245, P = 0.001). In contrast to DFS,
both coefficients are negative, indicating that both ER and
HSP27 have a positive effect with SR. The distinction
0.75 -
0.50 -
0.25 -
20-999
0 1 2 3 4 5 6
Time (years)
7 8 9 10
between SR and DFS was accentuated when the combined
ER and HSP27 phenotypes were compared (Figure 5).
HSP27 behaved as a surrogate for ER such that either ER or
HSP27 positivity indicated a longer SR than a negative
phenotype in the long (>4 years) but not short term (<3
years).
HSP27 stain index is a multiple of cellularity and stain
intensity. Where stain index was significant, staining intensity
and cellularity were separately assessed. For the SR
univariate analysis, stain intensity was significant
(coefficient =- 0.293, standard error = 0.0958, P = 0.003) but
cellularity only approached significance (coefficient = 0.203,
standard error = 0.1110, P= 0.07). Considering the multi-
variate analysis (see below) for SR, staining intensity could
replace the index with little difference in the fit of the model
or the other covariates (data not shown).
Overall survival
There were 361 patients and 117 events. As high HPS27
predicts for short DFS but long SR, HSP27 has no relation-
ship to overall survival (univariate Cox,
coefficient = - 0.016, standard error 0.0224, P = 0.5),
whereas highly significant effects of ER, PR, stage, nodal
status (all P<0.001) and histological grade (P = 0.01) were
obtained (Table II).
Multivariate analysis
Putting all the variables with P<0.1 in univariate analysis
into a stepwise Cox proportional hazards regression proce-
dure gives a final model containing the variables showing an
independent prognostic importance. HSP27 is not of indpen-
dent prognostic importance for DFS or OS (forcing this
covariate into either model gives P>0.2) and is only of
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Figure 4 Influence of a oestradiol receptor and b HSP727 levels
on survival from first relapse. Abbreviations are as described in
Figure 1. The numbers of patients at risk at 5 years are: a,
0-9 = 1, 10-19 = 1, 20-999 = 26, Chi-square 14.64,
P=<0.001. b, 0-2=4, 2.1-7=8, 7.1-25= 16, Chi-square
12.71, P=0.002.
Table H Overall survival
Variable No. ofpatients Log rank P-value
HSP27 360 0.9 0.7
ER 346 15.3 <0.001
PR 331 15.3 <0.001
Stage 361 35.8 <0.001
Nodal status 361 32.3 <0.001
Age 361 0.2 0.9
Tumour size 349 13.6 0.003
Grade 282 12.2 0.01
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Figure 5 Influence of combined oestradiol receptor (ER) and
HSP27 (I) phenotypes on survival from first relapse. Abbrevia-
tions are as described in Figure 3. The numbers ofpatients at risk
at 5 years are: ER I+ = 23, ER- I+ = 1; ER' I =4, ER-
I-= 0, Chi-square 20.92, P<0.01.
Table III Coefficient of HSP27 (s.e.) in multivariate Cox regression model
Disease-free Survival from Overall
Variables survival first relapse survival
Alla NS -0.051 (0.029)b NS
P = 0.07
Omit grade NS NS NS
Omit ER and PR NS -0.105 (0.027) - 0.053 (0.025)
P =0.0001 P = 0.03
Omit grade, ER and PR NS -0.109 (0.027) - 0.052 (0.025)
P<0.0001 P= 0.04
aGrade, ER, PR, nodal status, menstrual status, age, tumour size and histology.
bA negative coefficient indicates a positive effect with survival. Standard errors are
contained within the brackets. NS, not significant; s.e. standard error.
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borderline significance in SR (coefficient = - 0.0512, stan-
dard error = 0.0287, P = 0.07). In this latter case, the
coefficient being negative means that a higher value for
HSP27 increases survival.
Multivariate analysis was also used to see if HSP27 was of
independent prognostic importance in four particular cir-
cumstances (Table III): (i) with grade, ER and PR available;
(ii) with ER and PR available but not grade; (iii) with grade
available, no ER or PR; (iv) with none of grade, ER or PR
available.
In all cases index, nodal status, menstrual status, age,
tumour size, and histology were available.
From this table, adjusting for other variables as indicated,
index is independently prognostic for SFR or OS, with low
HSP27 indicating poor survival only when ER and PR are
not available. Even if neither grade, ER or PR is available,
HSP27 is not independently prognostic for DFS.
Discussion
There are clearly divergent influences of HSP27 on DFS and
SR, the reasons for which are unknown. The positive
association between high HSP27 staining and long SR agrees
well with the published literature on its association with ER
(Dunn et al., 1993) and their ability to predict for hormone
responsiveness of advanced breast cancer (King et al., 1987).
Women with breast cancers that respond to hormone treat-
ment have a longer survival from first relapse than those with
unresponsive tumours. Also, the correlation of high HSP27
with short DFS reported here is in broad agreement with the
previous publication of Thor et al. (1991), although
differences exist in respect of the nodal groups. For HSP27
alone we found an effect in node-negative but not -positive
patients, whereas Thor et al. (1991) obtained the opposite
result and Tandon et al. (1991) reported the same result as
ourselves. Danestrup et al. (1991) found no correlation
between HSP27 and disease-free survival.
None of these publications commented on the biological
behaviour of different HSP27 and ER phenotypes. Combina-
tion of these two variables generated significant differences in
DFS among the four phenotypes in both node-negative and
-positive groups. As ER' HSP27+ tumours recur more
rapidly than the ER' HSP27- ones, a positive link between
HSP27 and growth rate is plausible, which is supported by
other data. Antisense oligonucleotides directed against
HSP27 mRNA inhibit the proliferation of ER', ZR75
human breast cancer cells in parallel with decreased HSP27
levels (D.K. Dunn & R.J.B. King, in preparation), while high
levels of HSP27 in normal endometrial epithelium (King et
al., 1987) and normal mammary epithelium (King et al.,
1993) correlate with proliferative activity at different stages of
the menstrual cycle. Those data on normal epithelia would
also suggest that HSP27 is linked to proliferation rather than
to a specific hormonal environment as endometrial prolifera-
tion is stimulated by oestrogen whereas breast correlates with
a progestational state (King, 1992). Interestingly, high HSP27
also correlates with rapid recurrence of gastric cancer (Har-
rison et al., 1991) so its relevance may extend beyond
endocrine-related cancers. These data linking high HSP27
with rapid proliferation could provide an explanation for the
former's correlation with short DFS, but why this should be
confined to node-negative patients remains an enigma. Pos-
sibly other biological features associated with metastasis
override the proliferation effect. However, the putative link
between HSP27 and proliferation cannot explain the positive
correlation between high HSP27 hormone sensitivity and
good survival from first recurrence; in general, hormone-
sensitive breast tumours proliferate more slowly than their
insensitive counterparts (McGuire, 1987). This link with hor-
mone response is nevertheless compatible with the associa-
tion between HSP27 and ER discussed earlier.
The switch from HSP27 being a bad to a good prognostic
factor in early and advanced breast cancer respectively must
have an as yet unidentified biological explanation. Little is
known about the function of HSP27, although its initial
description as a heat shock protein links it to larger sized
members of this class of proteins which have multiple func-
tions related to many aspects of protein organisation and
transport (Georgopoulos, 1992; Gething & Sambrook, 1992);
beyond this it is not possible to formulate a unitary model
for the role of HSP27 in cell function. It is increased by
oestrogens in endometrial epithelium (King et al., 1987) and
some, but not all, breast cancer cell lines (Dunn et al., 1993)
and by progestins in endometrial stroma (Padwick et al.,
1988) and normal breast epithelium (King et al., 1993), and is
constitutively expressed in cervix (Hendry et al., 1988). It is
up-regulated in breast cancers (King et al., 1987) and in
virally transformed cells (Zantema et al., 1989) and in some
other cancers such as stomach (Harrison et al., 1991) and
brain cancer (Kato et al., 1992) and certain leukaemias
(Strahler et al., 1991). HSP27 also has a complex relationship
to chemotherapeutic drug sensitivity; drug resistance can be
associated with increased (Huot et al., 1987; Ciocca et al.,
1992) or decreased (Whelan & Hill, 1993; Dunn et al., 1993)
HSP27 depending on the drug in question and the experi-
mental system used. The simplest explanation of these diverse
correlations is that HSP27 is involved in many different cell
functions, possible by influencing the structure of different
proteins in different cells. This paper suggests that studies
along these lines will be rewarding at both a basic and
clinical level.
These data linking HSP27 with both growth and hormone
sensitivity are of biological interest, but the ability to identify
good and poor prognosis groups, especially in node-negative
patients, may also have clinical relevance. In early-stage
disease selection of high-risk patients, especially in node-
negative women, is important in the context of not giving
adjuvant treatment to women who have a high probability of
long, normal life without it (McGuire, 1989; Sigurdsson et
al., 1990). Given the abundance of HSP27 and its simple,
inexpensive immunohistochemical assay, its use as a prognos-
tic factor for node-negative breast cancer should be con-
sidered. In advanced cancer high levels of HSP27 are
indicative of a long survival probably because of the link
with hormone response. ER assays have rightly been used to
predict this feature (Jordan et al., 1988) but our data
reported here reinforce the previous suggestion (King et al.,
1987) that HSP27 may achieve the same objective and that,
because of its abundance, lack of influence of age and pos-
sibly treatment regimens on amounts and ease of assay,
HSP27 assays have some advantages over those for ER. If
ER and PR values are not available, immunohistochemical
evaluation of HSP27 is an effective method of obtaining
equivalent clinical information.
We thank Rosemary Millis for supplying the tissue sections and
pathology data and Walter Gregory (both Clinical Oncology Unit,
Guy's Hospital) for abstracting the relevant clinical data from their
database.
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